CHRONIC MYELOMONOCYTIC LEUKEMIA
Clinical trials for CHRONIC MYELOMONOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new CHRONIC MYELOMONOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising combo for tough blood cancer hits roadblock
Disease control TerminatedThis study looked at combining two drugs, venetoclax and azacitidine, to treat people with a serious type of bone marrow cancer called high-risk myelodysplastic syndrome (MDS). The goal was to find the safest dose and see if the combination could shrink or control the cancer. The…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:06 UTC
-
Experimental combo for tough blood cancers tested, but trial stopped early
Disease control TerminatedThis early-phase study tested a new drug called DSP107 combined with standard chemotherapy drugs (azacitidine with or without venetoclax) in adults with acute myeloid leukemia, myelodysplastic syndrome, or chronic myelomonocytic leukemia that had returned or not responded to up t…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Kahr Medical • Aim: Disease control
Last updated May 26, 2026 05:05 UTC
-
Promising combo for tough leukemias hits roadblock: trial ends early
Disease control TerminatedThis study tested a combination of two drugs, venetoclax and decitabine, in 235 people with certain blood cancers (like acute myeloid leukemia and high-risk myelodysplastic syndrome) that either came back or didn't respond to prior treatment, or in older adults who couldn't handl…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 18, 2026 12:00 UTC